{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T09:12:06Z","timestamp":1776244326766,"version":"3.50.1"},"reference-count":62,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AO"],"abstract":"<jats:p>Background and purpose: We aimed to describe temporal changes in diagnostic work-up, treatment, and prostate cancer (PCa) mortality in locally advanced PCa in 2016\u20132024 in Sweden. Patient\/material and methods: Men registered in the National Prostate Cancer Register of Sweden in 2016\u20132024 with locally advanced PCa; clinical T stage 3\u20134, no distant metastases, and prostate-specific antigen &lt;\u2009100 ng\/ml were included. We computed the proportion of use of prostate magnetic resonance imaging (MRI) before biopsy, radical prostatectomy, radical radiotherapy, androgen deprivation therapy, and abiraterone, and described the trend in PCa mortality across three calendar periods.Results: During the 9-year study period 7,484 men with locally advanced PCa were identified. Use of MRI before biopsy increased from 3% in 2016 to 73% in 2024. Concomitantly, radical treatment increased from 35% to 48%, entirely due to increased use of radiotherapy. Abiraterone was not used before 2022 but 31% received this treatment in 2024. The 3-year PCa mortality decreased from 8% (95% confidence interval [CI]: 7\u20139) in 2016\u20132018 to 6% (95% CI: 4\u20138) in 2022\u20132024. Interpretation: In this nationwide, population-based study of men with locally advanced PCa, the use of MRI before biopsy, radical radiotherapy, and treatment with abiraterone increased over time. These changes coincided with a modest decrease in 3-year PCa mortality.<\/jats:p>","DOI":"10.2340\/ao.v65.45593","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T08:35:26Z","timestamp":1776242126000},"page":"282-288","source":"Crossref","is-referenced-by-count":0,"title":["Temporal trends in diagnostic work-up, treatment, and mortality in locally advanced prostate cancer in 2016\u20132024: nationwide, population-based study in Sweden"],"prefix":"10.2340","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5880-0584","authenticated-orcid":false,"given":"Armando","family":"Galdieri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7181-7083","authenticated-orcid":false,"given":"Hans","family":"Garmo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8850-7863","authenticated-orcid":false,"given":"Rolf","family":"Gedeborg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2404-5890","authenticated-orcid":false,"given":"Mats","family":"Ahlberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2783-3542","authenticated-orcid":false,"given":"Orrason Andri","family":"Wilberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3654-1629","authenticated-orcid":false,"given":"Eugenio","family":"Ventimiglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3922-5561","authenticated-orcid":false,"given":"P\u00e4r","family":"Stattin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8906-6967","authenticated-orcid":false,"given":"Marcus","family":"Westerberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1183","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"149503","doi-asserted-by":"crossref","unstructured":"Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389(10071):815\u201322.","DOI":"10.1016\/S0140-6736(16)32401-1"},{"key":"149504","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0140-6736(16)32401-1","DOI":"10.1016\/S0140-6736(16)32401-1"},{"key":"149505","doi-asserted-by":"crossref","unstructured":"Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med. 2018;378(19):1767\u201377.","DOI":"10.1056\/NEJMoa1801993"},{"key":"149506","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa1801993","DOI":"10.1056\/NEJMoa1801993"},{"key":"149507","doi-asserted-by":"crossref","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;396(10255):1208\u201316.","DOI":"10.1016\/S0140-6736(20)30314-7"},{"key":"149508","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0140-6736(20)30314-7","DOI":"10.1016\/S0140-6736(20)30314-7"},{"key":"149509","doi-asserted-by":"crossref","unstructured":"Freedland SJ, Nair S, Lin X, Karsh L, Pieczonka C, Potluri R, et al. A US real-world study of treatment patterns and outcomes in localized or locally advanced prostate cancer patients. World J Urol. 2023;41(12):3535\u201342.","DOI":"10.1007\/s00345-023-04680-w"},{"key":"149510","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s00345-023-04680-w","DOI":"10.1007\/s00345-023-04680-w"},{"key":"149511","doi-asserted-by":"crossref","unstructured":"Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7\/SFUO-3): an open randomised phase III trial. Lancet. 2009;373(9660):301\u20138.","DOI":"10.1016\/S0140-6736(08)61815-2"},{"key":"149512","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0140-6736(08)61815-2","DOI":"10.1016\/S0140-6736(08)61815-2"},{"key":"149513","doi-asserted-by":"crossref","unstructured":"Foss\u00e5 SD, Wiklund F, Klepp O, Angelsen A, Solberg A, Damber JE, et al. Ten- and 15-yr prostate cancer-specific mortality in patients with nonmetastatic locally advanced or aggressive intermediate prostate cancer, randomized to lifelong endocrine treatment alone or combined with radiotherapy: final results of the Scandinavian Prostate Cancer Group-7. Eur Urol. 2016;70(4):684\u201391.","DOI":"10.1016\/j.eururo.2016.03.021"},{"key":"149514","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.eururo.2016.03.021","DOI":"10.1016\/j.eururo.2016.03.021"},{"key":"149515","doi-asserted-by":"crossref","unstructured":"Mason MD, Parulekar WR, Sydes MR, Brundage M, Kirkbride P, Gospodarowicz M, et al. Final report of the intergroup randomized study of combined androgen-deprivation therapy plus radiotherapy versus androgen-deprivation therapy alone in locally advanced prostate cancer. J Clin Oncol. 2015;33:2143\u201350.","DOI":"10.1200\/JCO.2014.57.7510"},{"key":"149516","doi-asserted-by":"crossref","unstructured":"Sargos P, Mottet N, Bellera C, Richaud P. Long-term androgen deprivation, with or without radiotherapy, in locally-advanced prostate cancer: updated results from a phase III randomised trial. BJU Int. 2019.","DOI":"10.1111\/bju.14768"},{"key":"149517","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bju.14768","DOI":"10.1111\/bju.14768"},{"key":"149518","doi-asserted-by":"crossref","unstructured":"Demogeot N, Sargos P, Salleron J, Gu\u00e9rif S, de Crevoisier R, Calais G, et al. Short-term androgen deprivation therapy and high-dose radiotherapy in intermediate- and high-risk localized prostate cancer: results from the GETUG 14 randomized phase 3 trial. Eur Urol. 2025;88(5):510\u20138.","DOI":"10.1016\/j.eururo.2025.07.019"},{"key":"149519","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.eururo.2025.07.019","DOI":"10.1016\/j.eururo.2025.07.019"},{"key":"149520","unstructured":"EAU Guidelines. Edn. presented at the EAU Annual Congress Amsterdam 2025. Arnhem, The Netherlands: EAU Guidelines Office; 2025."},{"key":"149521","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer. Version 4.2023. Plymouth Meeting, PA: National Comprehensive Cancer Network; 2023."},{"key":"149522","doi-asserted-by":"crossref","unstructured":"Eastham JA, Auffenberg GB, Barocas DA, Chou R, Crispino T, Davis JW, et al. Clinically localized prostate cancer: AUA\/ASTRO guideline, part I: introduction, risk assessment, staging, and risk-based management. J Urol. 2022;208(2):245\u201353.","DOI":"10.1097\/JU.0000000000002757"},{"key":"149523","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/JU.0000000000002757","DOI":"10.1097\/JU.0000000000002757"},{"key":"149524","doi-asserted-by":"crossref","unstructured":"Bratt O, Carlsson S, Fransson P, Thellenberg Karlsson C, Stranne J, Kindblom J, et al. The Swedish national guidelines on prostate cancer, part 1: early detection, diagnostics, staging, patient support and primary management of non-metastatic disease. Scand J Urol. 2022;56(4):265\u201373.","DOI":"10.1080\/21681805.2022.2094462"},{"key":"149525","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/21681805.2022.2094462","DOI":"10.1080\/21681805.2022.2094462"},{"key":"149526","doi-asserted-by":"crossref","unstructured":"Stranne J. 2023\/2024 update of the national prostate cancer guidelines in Sweden. Scand J Urol. 2024;59:210\u20131.","DOI":"10.2340\/sju.v59.42656"},{"key":"149527","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/sju.v59.42656","DOI":"10.2340\/sju.v59.42656"},{"key":"149528","doi-asserted-by":"crossref","unstructured":"Attard G, Murphy L, Clarke NW, Cross W, Jones RJ, Parker CC, et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet. 2022;399(10323):447\u201360.","DOI":"10.1016\/S0140-6736(21)02437-5"},{"key":"149529","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0140-6736(21)02437-5","DOI":"10.1016\/S0140-6736(21)02437-5"},{"key":"149530","doi-asserted-by":"crossref","unstructured":"Orrason AW, Westerberg M, Garmo H, Lissbrant IF, Robinson D, Stattin P. Changes in treatment and mortality in men with locally advanced prostate cancer between 2000 and 2016: a nationwide, population-based study in Sweden. BJU Int. 2020;126(1):142\u201351.","DOI":"10.1111\/bju.15077"},{"key":"149531","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bju.15077","DOI":"10.1111\/bju.15077"},{"key":"149532","doi-asserted-by":"crossref","unstructured":"Tomic K, Sandin F, Wigertz A, Robinson D, Lambe M, Stattin P. Evaluation of data quality in the National Prostate Cancer Register of Sweden. Eur J Cancer. 2015;51(1):101\u201311.","DOI":"10.1016\/j.ejca.2014.10.025"},{"key":"149533","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ejca.2014.10.025","DOI":"10.1016\/j.ejca.2014.10.025"},{"key":"149534","doi-asserted-by":"crossref","unstructured":"Bratt O, Butt ST, Carlsson C, Jelf-Eneqvist L, Gunnarsson O, Ihre A, et al. Swedish regional population-based organised prostate cancer testing: why, what and how? Scand J Urol. 2025;60:97\u2013104.","DOI":"10.2340\/sju.v60.43809"},{"key":"149535","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/sju.v60.43809","DOI":"10.2340\/sju.v60.43809"},{"key":"149536","doi-asserted-by":"crossref","unstructured":"Stattin P. How to improve cancer care by use of guidelines and quality registers. Scand J Urol. 2024;59:190\u20132.","DOI":"10.2340\/sju.v59.42272"},{"key":"149537","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/sju.v59.42272","DOI":"10.2340\/sju.v59.42272"},{"key":"149538","doi-asserted-by":"crossref","unstructured":"Westerberg M, Holm L, Garmo H, Stattin P, Gedeborg R. Cohort profile update: the National Prostate Cancer Register of Sweden and PCBase. Int J Epidemiol. 2025;54(5):dyaf172.","DOI":"10.1093\/ije\/dyaf172"},{"key":"149539","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/ije\/dyaf172","DOI":"10.1093\/ije\/dyaf172"},{"key":"149540","doi-asserted-by":"crossref","unstructured":"Westerberg M, Ahlberg M, Orrason AW, Gedeborg R. Assessment of variability in life expectancy in older men by use of new comorbidity indices: a nationwide population-based study. Scand J Urol. 2024;59:207\u20139.","DOI":"10.2340\/sju.v59.42504"},{"key":"149541","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/sju.v59.42504","DOI":"10.2340\/sju.v59.42504"},{"key":"149542","doi-asserted-by":"crossref","unstructured":"Westerberg M, Irenaeus S, Garmo H, Stattin P, Gedeborg R. Development and validation of a multi-dimensional diagnosis-based comorbidity index that improves prediction of death in men with prostate cancer: nationwide, population-based register study. PLoS One. 2024;19(1):e0296804.","DOI":"10.1371\/journal.pone.0296804"},{"key":"149543","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1371\/journal.pone.0296804","DOI":"10.1371\/journal.pone.0296804"},{"key":"149544","doi-asserted-by":"crossref","unstructured":"Gedeborg R, Sund M, Lambe M, Plym A, Fredriksson I, Syrj\u00e4 J, et al. An aggregated comorbidity measure based on history of filled drug prescriptions: development and evaluation in two separate cohorts. Epidemiology. 2021;32(4):607\u201315.","DOI":"10.1097\/EDE.0000000000001358"},{"key":"149545","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/EDE.0000000000001358","DOI":"10.1097\/EDE.0000000000001358"},{"key":"149546","doi-asserted-by":"crossref","unstructured":"Van Hemelrijck M, Ventimiglia E, Robinson D, Gedeborg R, Holmberg L, Stattin, P, et al. Population-based estimates of age and comorbidity specific life expectancy: a first application in Swedish males. BMC Med Inform Decis Mak. 2022;22(1):35.","DOI":"10.1186\/s12911-022-01766-0"},{"key":"149547","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/s12911-022-01766-0","DOI":"10.1186\/s12911-022-01766-0"},{"key":"149548","doi-asserted-by":"crossref","unstructured":"Orrason AW, Scilipoti P, Garmo H, Gedeborg R, Styrke J, Westerberg M. Improved adherence to prostate cancer guidelines concomitant with public reporting: nationwide population-based study. Scand J Urol. 2025;60:50\u20138.","DOI":"10.2340\/sju.v60.43107"},{"key":"149549","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/sju.v60.43107","DOI":"10.2340\/sju.v60.43107"},{"key":"149550","doi-asserted-by":"crossref","unstructured":"Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet. 2019;394(10196):385\u201395.","DOI":"10.1016\/S0140-6736(19)31131-6"},{"key":"149551","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0140-6736(19)31131-6","DOI":"10.1016\/S0140-6736(19)31131-6"},{"key":"149552","doi-asserted-by":"crossref","unstructured":"Fransson P, Nilsson P, Gunnlaugsson A, Beckman L, Tavelin B, Norman D, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial. Lancet Oncol. 2021;22(2):235\u201345.","DOI":"10.1016\/S1470-2045(20)30581-7"},{"key":"149553","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S1470-2045(20)30581-7","DOI":"10.1016\/S1470-2045(20)30581-7"},{"key":"149554","doi-asserted-by":"crossref","unstructured":"Stranne J, Brasso K, Brennhovd B, Johansson E, J\u00e4derling F, Kouri M, et al. SPCG-15: a prospective randomized study comparing primary radical prostatectomy and primary radiotherapy plus androgen deprivation therapy for locally advanced prostate cancer. Scand J Urol. 2018;52(5\u20136):313\u201320.","DOI":"10.1080\/21681805.2018.1520295"},{"key":"149555","doi-asserted-by":"crossref","unstructured":"Attard G, Murphy L, Clarke NW, Sachdeva A, Jones C, Hoyle A, et al. Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol. Lancet Oncol. 2023;24(5):443\u201356.","DOI":"10.1016\/S1470-2045(23)00148-1"},{"key":"149556","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S1470-2045(23)00148-1","DOI":"10.1016\/S1470-2045(23)00148-1"},{"key":"149557","doi-asserted-by":"crossref","unstructured":"Kv\u00e5le R, Ursin G, Ekanger C, M\u00f8ller B. Considerable decline in prostate cancer mortality in Nordic countries after 2000. Acta Oncol. 2025;64:114\u20139.","DOI":"10.2340\/1651-226X.2025.41334"},{"key":"149558","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/1651-226X.2025.41334","DOI":"10.2340\/1651-226X.2025.41334"},{"key":"149559","doi-asserted-by":"crossref","unstructured":"Albers P, Miandashti N, Broomfield S, Kinnaird A. Does the digital rectal exam still provide value in the age of MRI? Can Urol Assoc J. 2025;19(10):357\u201360.","DOI":"10.5489\/cuaj.9164"},{"key":"149560","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.5489\/cuaj.9164","DOI":"10.5489\/cuaj.9164"},{"key":"149561","doi-asserted-by":"crossref","unstructured":"Desai MM, Cacciamani GE, Gill K, Zhang J, Liu L, Abreu A, et al. Trends in incidence of metastatic prostate cancer in the US. JAMA Netw Open. 2022;5(3):e222246.","DOI":"10.1001\/jamanetworkopen.2022.2246"},{"key":"149562","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.2246","DOI":"10.1001\/jamanetworkopen.2022.2246"},{"key":"149563","doi-asserted-by":"crossref","unstructured":"Kleiburg F, Dirix P, Fonteyne V, Bral S, De Troyer B, Sautois B, et al. Stage migration on prostate-specific membrane antigen positron emission tomography\/computed tomography in comparison to conventional imaging in patients with high-risk prostate cancer referred for radiation therapy: results from the phase 2\/3 THUNDER trial. Eur Urol Oncol. 2025;8(5):1333\u20139.","DOI":"10.1016\/j.euo.2025.08.005"},{"key":"149564","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.euo.2025.08.005","DOI":"10.1016\/j.euo.2025.08.005"}],"container-title":["Acta Oncologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/45593\/53509","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/45593\/53509","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T08:35:46Z","timestamp":1776242146000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/view\/45593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":62,"URL":"https:\/\/doi.org\/10.2340\/ao.v65.45593","relation":{},"ISSN":["1651-226X"],"issn-type":[{"value":"1651-226X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]}}}